Krystal Biotech (KRYS) Financials

Krystal Biotech Inc (KRYS) recently released its financials, providing insights into the company's performance. Let's analyze their income statement to understand their earnings. With strong growth, KRYS reported a remarkable increase in total revenue, reaching a substantial figure. The company's gross profit also witnessed a significant surge, indicating their ability to generate revenue after deducting direct costs. Moreover, their operating cash flow demonstrated efficiency in managing day-to-day operations. KRYS achieved positive EBIT, showcasing their profitability before interest and taxes. Additionally, their EBITDA demonstrated strong financial performance, reflecting their ability to generate operating profits considering depreciation and amortization. Furthermore, the company's net income from stockholders exhibited their ability to distribute profits to shareholders.

Moving on to the balance sheet, KRYS showcased a healthy financial position. Their total assets have increased significantly, indicating their expansion and investment activities. The company's stockholders equity demonstrated steady growth, highlighting shareholder value creation. Moreover, KRYS had cash equivalents in their balance sheet, indicating their available liquid assets. Their net debt remained under control, showcasing sound financial management. Additionally, the company had total debt, indicating their utilization of borrowed funds for various activities. KRYS also had total liabilities that they need to settle in the future. The cash flow analysis revealed a positive financing cash flow, suggesting funds raised through financing activities. Furthermore, the investing cash flow demonstrated their capital expenditure and investment activities. The operating cash flow depicted positive cash flow generated from day-to-day operations. KRYS also generated free cash flow, implying their ability to invest in future growth initiatives.